Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
NCT04839705
Recruiting
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: University of Pennsylvania Health Systems, Philadelphia, Pennsylvania
Conditions: Wide Neck Bifurcation Intracranial Aneurysms
Register for Updates
Patient Navigation to Improve Surgical Access in Primary Hyperparathyroidism
NCT06562881
Recruiting
The goal of this study is to address surgical health equity in historically marginalized participants with primary hyperparathyroidism (PHPT). The main questions that this study aims to answer are, how does patient navigation impact: * The proportion of PHPT participants undergo parathyroidectomy? * The proportion of PHPT participants who complete surgical consultation? * Time to surgical consultation? * Time to surgery?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hyperparathyroidism, Primary
Register for Updates
Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)
NCT06263426
Recruiting
This research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with vs without HIV.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Hiv
Register for Updates
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
NCT06165341
Recruiting
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually endstage liver disease. Fazirsiran is a medicine that reduces the creation of... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2025
Locations: Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Alpha1-Antitrypsin Deficiency
Register for Updates
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer)
Register for Updates
Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
NCT05826743
Recruiting
The purpose of this study is to evaluate the Colorectal Balloon Tube (hereinafter referred to as COLO-BT™) device, a single use, temporary intraluminal bypass device, intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)
Gender:
ALL
Ages:
Between 19 years and 80 years
Trial Updated:
06/12/2025
Locations: PennState Health - Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Colorectal Surgery, Colorectal Cancer, Rectal/Anal, Ileostomy - Stoma, Anastomotic Leakage
Register for Updates
Testing Responses of Young Adults to Intervention Messages for Promoting Physical Activity Trial
NCT05794178
Recruiting
The goal of this clinical trial is to test a precision (person-specific and context-sensitive) messaging algorithm for increasing physical activity and slowing weight gain in insufficiently-active young adults. The main questions it aims to answer are: * Does physical activity increase more when text messages are sent based on a precision rule for selecting and timing messages compared to when the same message content is selected and sent at random or not at all? * Do biological or social chara... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
06/12/2025
Locations: The Pennsylvania State University, University Park, Pennsylvania
Conditions: Physical Inactivity, Weight Gain
Register for Updates
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069
Recruiting
The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200603 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200603 as a single agent or combination therapy is determined. During the expansion part, participants will take... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
Register for Updates
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
NCT05329103
Recruiting
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumor
Register for Updates
Improving Rehabilitation for Veterans After Total Knee Arthroplasty Using Individualized Recovery Trajectories
NCT05288803
Recruiting
This study will examine the impact of a new clinical decision support tool for rehabilitation after total knee arthroplasty (TKA). Typically, TKA rehabilitation is generic with most patients receiving the same dosage and contents of rehabilitation despite notable diversity among patients who undergo TKA. The investigators clinical support decision tool is designed to help physical therapists tailor rehabilitation treatments and dosages to the individual needs, goals, and preferences of Veterans... Read More
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
06/12/2025
Locations: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania
Conditions: Total Knee Arthroplasty
Register for Updates
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
NCT05143177
Recruiting
This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to which patients will be randomized in a ratio of 1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks. The 2 arms are: placebo and DA-1229 10 mg Group. The study will have t... Read More
Gender:
ALL
Ages:
35 years and above
Trial Updated:
06/12/2025
Locations: University of Pittsburgh Medical Center, Mechanicsburg, Pennsylvania
Conditions: Calcific Aortic Valve Disease
Register for Updates
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Register for Updates